INmune Bio Inc

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

INmune Bio reports stable financials, eyes growth in diversified programs

INmune Bio's financials remain stable, with a strategic focus on advancing key programs and achieving upcoming milestones.
The company's strengths lie in efficient trial consolidation, diversification into solid tumors, and patient-centric treatment approaches.
Challenges include operational complexities, FDA holds, and the need for successful international site enrollments.
Opportunities for growth include new program launches, expansion into different therapeutic areas, and exploring combination therapies.

INmune Bio advances Alzheimer's and cancer treatments amidst financial strength

INmune Bio's Q1 2023 performance reflects a focus on advancing treatments for Alzheimer's, cancer, and other diseases, supported by a strong financial position.
While facing challenges such as FDA clinical hold and resource allocation, the company's commitment to innovation and diversification presents growth opportunities.
With upcoming milestones and a promising pipeline, INmune Bio is poised to make significant strides in addressing critical medical needs and expanding its therapeutic reach.

INmune Bio reports Q2 loss, progresses in Alzheimer's and solid tumors

INmune Bio's Q2 2023 earnings call highlighted progress in Alzheimer's and solid tumor treatments, with positive effects observed on gray matter microstructure.
The company's financials showed a net loss but with sufficient cash reserves for operations, while upcoming milestones signal growth potential.
Challenges include managing losses, regulatory progress, and market strategies, but opportunities lie in therapeutic advancements and diversification.

INmune Bio advances Alzheimer's and cancer trials amidst financial challenges

INmune Bio made progress in patient enrollment for Alzheimer's and prostate cancer trials, with a focus on regulatory milestones. Financially, the company reported a net loss but maintains a healthy cash position. Challenges include regulatory hurdles and competition, while opportunities exist in upcoming milestones and market expansion.

INmune Bio advances Alzheimer's and prostate cancer trials amid financial challenges

INmune Bio's Q4 2023 Earnings Call highlighted progress in Alzheimer's and prostate cancer trials, with positive regulatory developments. Financially, the company reported a net loss but maintains a healthy cash position. Analyst questions focused on trial specifics and market comparisons.

INmune Bio Inc advances Alzheimer's trials and secures funding for growth

INmune Bio Inc's Q2 2024 showcased progress in Alzheimer's trials, successful fundraising, and strategic milestones ahead
The company's leadership, financial stability, and upcoming trials position it well for growth and market recognition
While facing competitive challenges and operational complexities, INmune Bio Inc remains focused on innovation and market expansion

INmune Bio excels in clinical trials, secures funding for growth

INmune Bio's Q3 2024 earnings call highlighted strong clinical progress, financial growth, and a focus on data-driven decision-making for future success.
The company's emphasis on quality standards, innovative drug delivery, and promising trial results positions them well for upcoming milestones and market impact.
While facing inquiries and challenges, INmune Bio remains confident in its programs, signaling a resilient approach to addressing industry complexities and driving growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 16, 2023 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Wednesday, November 1, 2023 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023 and to provide a corporate update.

INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1

Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient's immune system to fight disease, announced today that RJ Tesi, MD, Chief Executive Officer, and David Moss, Chief Financial Officer, will participate in two September 2023 conferences.

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro ™ in patients with early Alzheimer's disease to the U.K.

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer's Disease

INmune Bio, Inc. (NASDAQ:INMB ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer & Chief Medical Officer Conference Call Participants Joel Beatty - Baird Operator Greetings, and welcome to the INmune Bio Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

INmune Bio, Inc. (INMB) Q2 2023 Earnings Call Transcript

BOCA RATON, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2023 and provides a business update.

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update

Boca Raton, FL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient's immune system to fight disease, announced today that RJ Tesi, MD, CEO and David Moss, Chief Financial Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 7 – 8, 2023.

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Monday, August 7, 2023 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer's Disease

Neutralizing soluble TNF with XPro™ promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Analysts at Baird initiated coverage of the immunology company INmune Bio with a price target more than double its current share price.  The firm issued an Outperform rating and target price of $16.

INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts say

BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio's CSO, will be giving the opening plenary lecture of the Presidential Symposium at the International Society of Cell and Gene Therapy (ISCT) in Paris, France on May 31st.

INmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).  The Company believes this is the first NK immunotherapy trial in men with mCRPC, which affects more than 80,000 men in the U.S.  The trial is expected to enroll the first of 30 patients in the second half of 2023. It will be opened at 4 more clinical study sites, with a goal to determine short and long-term safety of INKmune™, demonstrate the ability of INKmune™ to control prostate cancer tumor burden, and identify a dose of INKmune™ to be used in a future blinded randomized pivotal trial.

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

INmune Bio, Inc. (NASDAQ:INMB ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.

INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript

BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2023 and provides a business update.

INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update

Avalo Therapeutics

Oric Pharmaceuticals

Twist Bioscience Corp

Exact Sciences

Synlogic

Tenaya Therapeutic

Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person's body.

The 7 Best Biotech Stocks for Personalized Medicine Investors

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Wednesday, May 3, 2023 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

INmune Bio: Alzheimer's Disease Treatment Lottery Ticket.

INmune Bio: Alzheimer's Disease Treatment Lottery Ticket

TNF is involved in the development of Alzheimer's Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer's Disease

Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03

BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of INKmune™ to treat metastatic castration-resistant prostate cancer (mCRPC).

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

INmune Bio, Inc. (NASDAQ:INMB ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants David Moss - CFO RJ Tesi - CEO CJ Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Jason McCarthy - Maxim Group Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Greetings, and welcome to the INmune Bio Fourth Quarter and Full Year 2022 Earnings Call. This conference will be recorded.

INmune Bio, Inc. (INMB) Q4 2022 Earnings Call Transcript

Company to Host Conference Call Today, March 2, at 4:30pm ET Company to Host Conference Call Today, March 2, at 4:30pm ET

INmune Bio, Inc. Announces 2022 Results and Provides Business Update

Management to host conference call and webcast at 4:30 pm ET on that day

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces that it has received a combined approximately $6.4 million in research and development refunds from both Australia (~$3.7 million) and the United Kingdom (~$2.7 million). The Company will use the rebates to reinvest in its clinical programs, particularly the ongoing Phase 2 Alzheimer's Disease (AD) trial in Australia and Canada.

News for INmune Bio Inc Stock (INMB)